SCHEMBL7538747

SCHEMBL7538747

Clc1ccc2c(CCN3CCN(c4cccc5[nH]ccc45)CC3)c[nH]c2c1

nearest known ligand 0.59

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 5/20 0.59
GAA P10253 3/20 0.54
MAPT P10636 2/20 0.54
HTR6 P50406 4/20 0.54
KCNH2 Q12809 4/20 0.54
HTR7 P34969 2/20 0.53
DRD4 P21917 2/20 0.53
DRD3 P35462 2/20 0.53
HTR1A P08908 2/20 0.52
GOT1 P17174 3/20 0.50
HTR2A P28223 1/20 0.49
RECQL P46063 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7532842 0.93 HTR6 (0.62) DRD2GAAMAPTHTR6KCNH2
SCHEMBL7538010 0.90 DRD2 (0.55) DRD2HTR6KCNH2HTR7HTR1A
SCHEMBL7532948 0.88 DRD2 (0.66) DRD2GAAMAPTHTR7DRD4
SCHEMBL7532799 0.88 GAA (0.58) DRD2GAAMAPTHTR6KCNH2
SCHEMBL7531437 0.87 DRD2 (0.52) DRD2HTR6KCNH2HTR7HTR1A
SCHEMBL7538803 0.86 DRD2 (0.58) DRD2HTR6KCNH2HTR7HTR1A
SCHEMBL7533617 0.85 DRD2 (0.50) DRD2HTR6KCNH2HTR7HTR1A
SCHEMBL7531563 0.85 GOT1 (0.52) DRD2GAAMAPTHTR7DRD4
SCHEMBL7533845 0.84 DRD2 (0.52) DRD2HTR6KCNH2HTR7DRD3
SCHEMBL7533687 0.84 DRD2 (0.49) DRD2HTR6KCNH2DRD4DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020128272-A1 4,5,6, and 7-indole and indoline derivatives, their preparation and use H. LUNDBECK A/S (DK) 2002-09-12 US claimed
US-6391882-B1 PSYCHOLOGICAL DISORDERS; ANTIDEPRESSANTS H. LUNDBECK A/S (DK) 2002-05-21 US claimed
CN-1336925-A 4,5,6 and 7-indole and indoline derivatives, their prepn. and use LUNDBECK & CO AS H (DK) 2002-02-20 CN claimed
EP-1089997-A1 4,5,6 AND 7-INDOLE AND INDOLINE DERIVATIVES, THEIR PREPARATION AND USE H.Lundbeck A/S (DK) 2001-04-11 EP claimed
WO-1999067237-A1 4,5,6 AND 7-INDOLE AND INDOLINE DERIVATIVES, THEIR PREPARATION AND USE H. LUNDBECK A/S (DK) 1999-12-29 WO claimed
US-20020128272-A1 4,5,6, and 7-indole and indoline derivatives, their preparation and use H. LUNDBECK A/S (DK) 2002-09-12 US disclosed
US-6391882-B1 PSYCHOLOGICAL DISORDERS; ANTIDEPRESSANTS H. LUNDBECK A/S (DK) 2002-05-21 US disclosed
EP-1089997-A1 4,5,6 AND 7-INDOLE AND INDOLINE DERIVATIVES, THEIR PREPARATION AND USE H.Lundbeck A/S (DK) 2001-04-11 EP disclosed
WO-1999067237-A1 4,5,6 AND 7-INDOLE AND INDOLINE DERIVATIVES, THEIR PREPARATION AND USE H. LUNDBECK A/S (DK) 1999-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128272-A1 4,5,6, and 7-indole and indoline derivatives, their preparation and use HTR2C, HTR1A, HTR7 DRD2 49/4885GAA 4549/4885MAPT 2061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.